- Home
- GYRE vs PLAY Comparison
GYRE vs PLAY Comparison
Compare GYRE & PLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- PLAY
- Stock Information
- Founded
- GYRE 2002
- PLAY 1982
- Country
- GYRE United States
- PLAY United States
- Employees
- GYRE N/A
- PLAY N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- PLAY Restaurants
- Sector
- GYRE Health Care
- PLAY Consumer Discretionary
- Exchange
- GYRE Nasdaq
- PLAY Nasdaq
- Market Cap
- GYRE 897.1M
- PLAY 804.3M
- IPO Year
- GYRE N/A
- PLAY 1995
- Fundamental
- Price
- GYRE $9.53
- PLAY $19.86
- Analyst Decision
- GYRE
- PLAY Buy
- Analyst Count
- GYRE 0
- PLAY 6
- Target Price
- GYRE N/A
- PLAY $27.00
- AVG Volume (30 Days)
- GYRE 105.9K
- PLAY 1.1M
- Earning Date
- GYRE 05-09-2025
- PLAY 06-11-2025
- Dividend Yield
- GYRE N/A
- PLAY N/A
- EPS Growth
- GYRE N/A
- PLAY N/A
- EPS
- GYRE 0.04
- PLAY 1.46
- Revenue
- GYRE $100,643,000.00
- PLAY $2,132,700,000.00
- Revenue This Year
- GYRE $22.01
- PLAY $5.78
- Revenue Next Year
- GYRE $88.14
- PLAY $4.08
- P/E Ratio
- GYRE $213.36
- PLAY $13.71
- Revenue Growth
- GYRE N/A
- PLAY N/A
- 52 Week Low
- GYRE $6.11
- PLAY $15.08
- 52 Week High
- GYRE $19.00
- PLAY $57.10
- Technical
- Relative Strength Index (RSI)
- GYRE 55.67
- PLAY 52.79
- Support Level
- GYRE $8.51
- PLAY $18.71
- Resistance Level
- GYRE $9.98
- PLAY $21.50
- Average True Range (ATR)
- GYRE 0.61
- PLAY 0.99
- MACD
- GYRE 0.10
- PLAY 0.19
- Stochastic Oscillator
- GYRE 73.84
- PLAY 41.32
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.